Learning Point for Clinicians
Childhood-onset mitochondrial encephalomyopathies usually present with a progressive course with a fatal outcome. These assumed irreversible conditions prompt clinicians and parents to face end-of-life decisions for a young child. However, this unfortunate situation can be overcome via a molecular diagnosis that can grant a favorable prognosis with continuing intensive supportive care.
Case report Patient 1
A 6-week-old boy was admitted to the pediatric intensive care unit (PICU) for frequent choking and apnea, requiring gavage feeding and assisted ventilation. He developed generalized weakness and sucking difficulties soon after birth. He exhibited profound hypotonia and hyporeflexia. The serum lactate was 9.6 mmol/l (normal reference: 0.5-2.2) and the creatine kinase (CK) 700 U/l (normal reference: 200). Muscle biopsy from the biceps brachii suggested a mitochondrial myopathy with cytochrome c oxidase (COX) deficiency (Figure 1 ). Full mitochondrial DNA (mtDNA) sequencing isolated from blood leukocytes was performed and a m.14674T>C mt-tRNA Glu mutation was identified. This mutation was further confirmed by polymerase chain reaction (PCR)/restriction fragment length polymorphism (RFLP) analysis. Similarly, this mutation was also identified in the mother; however, the whole maternal families were asymptomatic. Subsequently, despite repeated PICU admissions for respiratory support over a 12-month period, his condition gradually improved. Head control was achieved at 5 months. At 8 months of age, nasogastric tube feeding and the ventilator were discontinued. He could sit independently at 10 months and could walk at 16 months. By 1 year of age, his serum lactate returned to normal. Currently, at 4.5 years of age, he has no prominent myopathic features and can run steadily without fatigue.
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Patient 2
A 14-day-old girl was admitted for respiratory distress together with high serum lactate (12.0 mmol/l) but normal CK. Subsequently, poor bulbar function and respiratory distress required frequent PICU admissions over an 8-month period. A muscle biopsy from the biceps brachii indicated COX-deficiency mitochondrial myopathy. The genetic analysis also confirmed a m.14674T>C mt-tRNA Glu mutation by PCR/RFLP method. Her mother and maternal families were asymptomatic. Accordingly, the parents were reassured with the favorable prognosis and intensive supportive care was continued. She was weaned from artificial ventilation and gavage feeding at 10 months of age. Currently, at 3 years of age, she can run slowly.
Discussion
The early infantile onset of mitochondrial diseases is often associated with lethal encephalomyopathy and multi-organ involvement, leading to death in early childhood. 1 Deficiency of mitochondrial COX, a multisubunit assembly present in the inner membrane, usually causes progressive symptoms, called infantile fatal form. Interestingly, a distinct subtype, termed infantile reversible COX-deficiency myopathy, is characterized by spontaneous improvement both in clinical and pathological features. The floppy infant syndrome invariably manifests, requiring vigorous intensive care in infancy; however, spontaneous improvement ensues and the children are usually normal by 2 or 3 years of age. 2, 3 The causative gene has been recently identified as homoplasmic m.14674T>C or m.14674T>G mt-tRNA Glu mutation. 4, 5 This simple genetic test is crucial for prognosis and management, because both clinical and histopathological features between fatal and benign reversible COXdeficiency myopathies are indistinguishable in infancy.
In conclusion, we suggest that screening for this mutation is imperative for floppy infants with suspected mitochondrial myopathy. Diagnosis of reversible COX-deficiency myopathy at the molecular level warrants pediatric neurologists and intensivists to efficiently identify children with a favorable outcome for continuing respiratory support from those with fatal mitochondrial presentation in infancy.
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